References of "Palazzo, Claudio"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLiposomes and drug-in-cyclodextrin-in-liposomes formulations encapsulating 17β-estradiol: an innovative drug delivery system that prevents the activation of the membrane-initiated steroid signaling (MISS) of estrogen receptor α
Gallez, Anne ULiege; Palazzo, Claudio ULiege; Blacher, Silvia ULiege et al

in International Journal of Pharmaceutics (2020), 573

The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the ... [more ▼]

The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the incomplete understanding of nano-bio interactions. Specifically, the impact that inclusion of drug into liposomes or of drug-in-cyclodextrin-in liposomes (DCL) could have on the molecular and cellular mechanism of drug action is largely unknown. As a proof of concept, we evaluated the impact of 17β-estradiol (E2) included into liposomes or DCL on estrogen receptor (ER)α signaling pathways. Indeed, ERα relays the pleiotropic actions of E2 in physiology and pathophysiology through two major pathways: (1) the genomic/nuclear effects associated to the transcriptional activity of the ERα and (2) the rapid/nongenomic/membrane-initiated steroid signaling (MISS) effects related to the induction of fast signaling pathways occurring when ERα is anchored to the plasma membrane. We evidenced that the inclusion of E2 into liposomes (Lipo-E2) or into DCL (DCL-E2) prevented the activation of the rapid/nongenomic/extranuclear/MISS pathway of ERα, while the activation of the genomic/nuclear pathway was maintained. These results support that Lipo-E2 and DCL-E2 could be a useful tool to delineate the complex molecular mechanisms associated to ERα. In conclusion, this study supports the notion that inclusion of drugs into liposomes or DCL could modify some specific pathways of their molecular and cellular mechanisms of action. These results emphasized that attention should be paid to nano-bio interactions induced by the use of nanovectors in medicine. [less ▲]

Detailed reference viewed: 63 (23 ULiège)
Full Text
Peer Reviewed
See detailDevelopment of injectable liposomes and drug-in-cyclodextrin-in-liposome formulations encapsulating estetrol to prevent cerebral ischemia of premature babies.
Palazzo, Claudio ULiege; Laloy, Julie; Delvigne, Anne Sophie et al

in European Journal of Pharmaceutical Sciences (2019), 9(127), 52-59

Neonatal Hypoxic-Ischemic Encephalopathy (HIE), a brain disease due to brain hypoxia along with ischemia and reduced cerebral blood flow, is one of the primary reasons of severe injury among babies ... [more ▼]

Neonatal Hypoxic-Ischemic Encephalopathy (HIE), a brain disease due to brain hypoxia along with ischemia and reduced cerebral blood flow, is one of the primary reasons of severe injury among babies prematurely born. No efficacy treatment is available to the present day. Estetrol (E4), a major estradiol metabolite, has an important role in the brain development and protection. The aim of this study is to develop new injectable liposome and drug-in-cyclodextrin-in-liposome (DCL) formulations, encapsulating E4 in order to enhance its crossing through the blood-brain barrier (BBB). Liposome and DCL formulations were prepared and were physiochemically characterized. Stability in foetal bovine serum (FBS) was evaluated. LDH and MTS tests on endothelial, neuronal and BBB model cells, as well as hemocompatibility of the nanovectors were performed in vitro. In vitro BBB passage was evaluated using human BBB cell line (hCMEC/D3). All the formulations had average particle size below 150 nm, polydispersity index below 0.10 and ζ potential around + 30 mV. The encapsulation efficacy for liposomes was between 3% and 10% while those of DCL are between 15% and 35%. The effect of liposome and DCL formulations on cell viability and integrity was evaluated. The results showed no toxic effects on all the tested cell lines. Hemocompatibility tests showed no hemolysis, platelet aggregation or effects on coagulation, confirming the possibility of the formulations to be intravenously administrated. BBB passage tests highlighted the capability of the formulations to pass the BBB and reach the brain. Therefore, the formulations are promising drug delivery system to target estrogens to the brain, due to their physiochemical characteristics. [less ▲]

Detailed reference viewed: 88 (20 ULiège)
See detailInclusion of 17β-estradiol into liposome prevent the activation of membrane initiated signaling of ERalpha
Gallez, Anne ULiege; Palazzo, Claudio ULiege; Evrard, Brigitte ULiege et al

Poster (2018)

Estrogens are implicated in many physiological and pathological processes thanks to their interaction with estrogen receptors (ERs). The estrogen receptor alpha (ERα) controls reproduction, normal mammary ... [more ▼]

Estrogens are implicated in many physiological and pathological processes thanks to their interaction with estrogen receptors (ERs). The estrogen receptor alpha (ERα) controls reproduction, normal mammary gland development and breast cancer progression. The activation of ERα by estrogens, especially by 17β-estradiol (E2), leads to two major pathways: (1) the genomic effects associated to the transcriptional activity of the ERα and (2) the MISS (Membrane Initiated Steroid Signaling) effects related to the induction of fast signaling pathways occurring when ERα is anchored to the plasma membrane. Liposome are small non-toxic and biodegradable vectors widely studied for treatment of pathologies, like multiple sclerosis, Parkinson and Alzheimer disease and cancer. The encapsulation of several types of molecules (proteins, DNA and steroids), the protection of the activity and the improvement of the pharmacokinetic properties of these compounds represent the main advantages of liposome’s use. However, the impact of the encapsulation on molecular mechanisms is not yet established. As a proof of concept, we evaluate the impact of E2 inclusion into liposome (named POPC E2) in vitro and in vivo on ERα signaling pathway activation. [less ▲]

Detailed reference viewed: 43 (5 ULiège)
Full Text
Peer Reviewed
See detailDevelopment and evaluation of injectable nanosized drug delivery systems for apigenin
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Laloy, Julie et al

in International Journal of Pharmaceutics (2017), 532(2), 757-768

The purpose of this study was to develop different injectable nanosized drug delivery systems (NDDSs) i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule (PNC) encapsulating apigenin (AG) and ... [more ▼]

The purpose of this study was to develop different injectable nanosized drug delivery systems (NDDSs) i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule (PNC) encapsulating apigenin (AG) and compare their characteristics to identify the nanovector(s) that can deliver the largest quantity of AG while being biocompatible. Two liposomes with different surface characteristics (cationic and anionic), a LNC and a PNC were prepared. A novel tocopherol modified poly(ethylene glycol)-b-polyphosphate block-copolymer was used for the first time for the PNC preparation. The NDDSs were compared by their physicochemical characteristics, AG release, storage stability, stability in serum, complement consumption and toxicity against a human macrovascular endothelial cell line (EAhy926). The diameter and surface charge of the NDDSs were comparable with previously reported injectable nanocarriers. The NDDSs showed good encapsulation efficiency and drug loading. Moreover, the NDDSs were stable during storage and in fetal bovine serum for extended periods, showed low complement consumption and were non-toxic to EAhy926 cells up to high concentrations. Therefore, they can be considered as potential injectable nanocarriers of AG. Due to less pronounced burst effect and extended release characteristics, the nanocapsules could be favorable approaches for achieving prolonged pharmacological activity of AG using injectable NDDS. [less ▲]

Detailed reference viewed: 110 (34 ULiège)
Full Text
See detailEnhancement of the internalization of lipid nanocapsules in human glioblastoma cells: Effect of surface concentration of NFL peptide
Karim, Reatul ULiege; Lepeltier, Elise; Palazzo, Claudio ULiege et al

Poster (2017)

Le glioblastome multiforme (GBM) est un des cancers les plus fatal, avec une médiane de survie de 14 mois après traitement. Il est donc nécessaire de développer de nouvelles thérapies plus efficaces. La ... [more ▼]

Le glioblastome multiforme (GBM) est un des cancers les plus fatal, avec une médiane de survie de 14 mois après traitement. Il est donc nécessaire de développer de nouvelles thérapies plus efficaces. La fonctionnalisation en surface de nanocapsules lipidiques (LNC) avec le peptide NFL-TBS.40-63 (NFL) a déjà montré une amélioration de leur internalisation dans des cellules de glioblastome murin. Le but de cette étude a été d’évaluer l’impact de la concentration en NFL présente en surface des LNC sur l’internalisation de ces dernières dans des cellules humaines de GBM U87MG. De plus, le mécanisme d’internalisation LNC-NFL a été étudié. Une sonde fluorescente (DiA) a été encapsulé dans : des LNC (F1), des LNC avec 0.86 % et 2.58 % (w/w) de NFL adsorbé à la surface (F2 et F3 respectivement). Des analyses par cytométrie en flux (FACS) ont révélé une internalisation cellulaire de F3 plus importante de 46.4 et 6.8 fois après 30 min, de 21.6 et 6.1 fois après 1 heure, de 31.5 et 1.6 fois après 6 heures et de 7.3 et 1.1 fois après 24 heures, comparés à F1 et F2 respectivement. L’internalisation de F3 dans les cellules U87MG s’est révélée être énergie-dépendant, avec comme mécanisme principal la macropinocytose. Les cinétiques de désorption du peptides (obtenues par dialyse de F3 dans du Tris-Buffer pH 7.4 à 37°C suivi par une HPLC analytique) ont montré que 66 % de NFL restaient à la surface des LNC après 6h de dialyse, montrant une désorption lente. De plus, les trois formulations ont montré une faible activation du complément. Du fait d’une internalisation significativement plus prononcée et rapide, F3 semble être prometteur pour améliorer l’efficacité des thérapies antiGBM. De plus, la lente désorption du NFL de la surface des LNC et la faible consommation du complément font de F3 une thérapie ciblé prometteuse contre le GBM. [less ▲]

Detailed reference viewed: 56 (4 ULiège)
Full Text
See detailNEW INJECTABLE LIPOSOME AND DRUG-IN-CYCLODEXTRIN-IN LIPOSOME SYSTEMS ENCAPSULATING ESTETROL FOR THE TREATMENT OF ISCHEMIA DISEASES IN PREMATURE BABIES
Palazzo, Claudio ULiege; Laloy, Julie; Delvigne, Anne-Sophie et al

Poster (2016, December)

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies ... [more ▼]

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies with motor, vision, hearing or mental deficiencies is still constant along the last twenty years. Moreover, no efficacy treatment is available to the present day. The estetrol (E4) has an important role in the brain development and protection. The aim of this study is to develop new injectable liposome and drug-in-cyclodextrin-in-liposome (DCL) formulations, encapsulating E4 in order to enhance its crossing through the blood-brain barrier (BBB). Methods: Cyclodextrins (CD) were used to increase E4 aqueous solubility. Liposome and DCL (E4-CD complex) formulations were prepared by thin-film hydration technique. The formulations were physicochemical characterized. LDH and MTS tests on endothelial, neuronal and BBB model cells were performed in vitro on the liposome formulation. Hemocompatibility of the formulations was evaluated on red blood cells, platelet aggregation and coagulation. BBB passage tests were performed using human BBB cell line (hCMEC/D3). Results: E4-CD complexes proportionally increased the solubility of the hormone. Liposomes and DCL encapsulating E4 were prepared. All the formulations had average particle size below 150 nm, polydispersity index below 0.10 and ζ potential around + 30 mV. The encapsulation efficacy for liposomes was between 3% and 10% while those of DCL are between 15% and 35%. Moreover, the formulations are capable to release 80 % (liposome) and 90 % (DCL) of encapsulated E4 after 3 h at 37°C. The effect of liposome and DCL formulations on cell viability and integrity was evaluated. The results showed no toxic effects on all the tested cell lines. Hemocompatibility tests showed no hemolysis, platelet aggregation or effects on coagulation, confirming the possibility of the formulations to be intravenously administrated. BBB passage tests highlighted the capability of the formulations to pass the BBB and reach the brain. Conclusions: New non-toxic, hemocompatible liposome and DCL formulations encapsulating E4 were prepared. The formulations are promising drug delivery system to target estrogens to the brain, due to their physiochemical characteristics. [less ▲]

Detailed reference viewed: 101 (14 ULiège)
Full Text
See detailDevelopment and comparison of liposomes and nanocapsules as injectable nanocarriers for poorly aqueous soluble drugs
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Laloy, Julie et al

Poster (2016, December)

About 90% of drugs in development phase have poor aqueous solubility. Liposomes and nanocapsules are promising approaches that enable parenteral administration of these drugs with possibilities of site ... [more ▼]

About 90% of drugs in development phase have poor aqueous solubility. Liposomes and nanocapsules are promising approaches that enable parenteral administration of these drugs with possibilities of site specific delivery. The objective of the study was to develop different liposomes and lipid nanocapsules entrapping a hydrophobic model molecule (apigenin (AG)), and to characterize and compare them as potential injectable nanocarriers (NCs) for drugs with low aqueous solubility. [less ▲]

Detailed reference viewed: 129 (12 ULiège)
Peer Reviewed
See detailINNOVATIVE INJECTABLE LIPOSOME AND DRUG-IN-CYCLODEXTRIN-IN LIPOSOME SYSTEMS ENCAPSULATING ESTETROL FOR THE TREATMENT OF ISCHEMIA DISEASES IN PREMATURE BABIES
Palazzo, Claudio ULiege; Laloy, Julie; Delvigne, Anne-Sophie et al

Conference (2016, September 28)

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies ... [more ▼]

Purpose: In 2010, almost 15 million of babies in the world are prematurely borned, 11.1 % of the total amount of alive children. Despite the better neonatology techniques, the number of preterm babies with motor, vision, hearing or mental deficiencies is still constant along the last twenty years. Moreover, no efficacy treatment is available to the present day. The estetrol (E4) has an important role in the brain development and protection. The aim of this study is to develop new injectable liposome and drug-in-cyclodextrin-in-liposome (DCL) formulations, encapsulating E4 in order to enhance its crossing through the blood-brain barrier (BBB). Methods: Hydroxypropyl-β-cyclodextrins (degrees of substitution 0.87 and 0.63) (HPβCD 0.87 and HPβCD 0.63) were used to increase E4 aqueous solubility. Liposome and DCL (E4-HPβCD 0.63 complex) formulations were prepared by thin-film hydration technique. The formulations were physicochemical characterized and stability in foetal bovine serum (FBS) was evaluated. LDH and MTS tests on endothelial, neuronal and BBB model cells were performed in vitro on the liposome formulation. Hemocompatibility of the formulations was evaluated on red blood cells, platelet aggregation and coagulation. BBB passage tests were performed using human BBB cell line (hCMEC/D3). Results: E4-HPβCD complexes proportionally increased the solubility of the hormone. Due to the lower solubility obtained with HPβCD ds 0.87, only HPβCD ds 0.63 was retained for future tests. Liposomes and DCL encapsulating E4 were prepared. All the formulations had average particle size below 150 nm, polydispersity index below 0.10 and ζ potential around + 30 mV. The encapsulation efficacy for liposomes was between 3% and 10% while those of DCL are between 15% and 35%. Moreover, the formulations are capable to release 80 % (liposome) and 90 % (DCL) of encapsulated E4 after 3 h at 37°C. The formulations, incubated in FBS at 37°C under gentle stirring, keep the same size and do not form protein corona up to 6 h. The effect of liposome and DCL formulations on cell viability and integrity was evaluated. The results showed no toxic effects on all the tested cell lines. Hemocompatibility tests showed no hemolysis, platelet aggregation or effects on coagulation, confirming the possibility of the formulations to be intravenously administrated. Preliminary BBB passage tests highlighted the capability of the formulations to pass the BBB and reach the brain. Conclusions: New non-toxic, hemocompatible liposome and DCL formulations encapsulating E4 were prepared. The formulations are promising drug delivery system to target estrogens to the brain, due to their physiochemical characteristics. Aknowledgment : The authors thank Estetra SPRL for providing Estetrol. [less ▲]

Detailed reference viewed: 106 (16 ULiège)
Peer Reviewed
See detailDEVELOPMENT OF NOVEL CATIONIC AND LIGAND-GRAFTED ANIONIC LIPOSOMES FOR BRAIN-TARGETED DRUG DELIVERY
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Laloy, Julie et al

Poster (2016, September 27)

Detailed reference viewed: 37 (7 ULiège)
Full Text
Peer Reviewed
See detailNanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Evrard, Brigitte ULiege et al

in Journal of Controlled Release (2016), 10(227), 23-37

Glioblastoma multiforme, a grade IV glioma, is the most frequently occurring and invasive primary tumor of the central nervous system, which causes about 4% of cancer-associated-deaths, making it one of ... [more ▼]

Glioblastoma multiforme, a grade IV glioma, is the most frequently occurring and invasive primary tumor of the central nervous system, which causes about 4% of cancer-associated-deaths, making it one of the most fatal cancers. With present treatments, using state-of-theart technologies, the median survival is about 14 months and 2 year survival rate is merely 3–5%. Hence, novel therapeutic approaches are urgently necessary. However, most drug molecules are not able to cross the blood–brain barrier, which is one of the major difficulties in glioblastoma treatment. This review describes the features of blood–brain barrier, and its anatomical changes with different stages of tumor growth. Moreover, various strategies to improve brain drug delivery i.e. tight junction opening, chemical modification of the drug, efflux transporter inhibition, convection-enhanced delivery, craniotomy-based drug delivery and drug delivery nanosystems are discussed. Nanocarriers are one of the highly potential drug transport systems that have gained huge research focus over the last few decades for site specific drug delivery, including drug delivery to the brain. Properly designed nanocolloids are capable to cross the blood–brain barrier and specifically deliver the drug in the brain tumor tissue. They can carry both hydrophilic and hydrophobic drugs, protect them from degradation, release the drug for sustained period, significantly improve the plasma circulation half-life and reduce toxic effects. Among various nanocarriers, liposomes, polymeric nanoparticles and lipid nanocapsules are the most widely studied, and are discussed in this review. For each type of nanocarrier, a general discussion describing their composition, characteristics, types and various uses is followed by their specific application to glioblastoma treatment. Moreover, some of the main challenges regarding toxicity and standardized evaluation techniques are narrated in brief. [less ▲]

Detailed reference viewed: 115 (27 ULiège)
See detailDRUG DELIVERY NANOCARRIERS TO CROSS OF THE BLOOD-BRAIN BARRIER
Palazzo, Claudio ULiege; Karim, Reatul ULiege; Evrard, Brigitte ULiege et al

in Grumezescu, Alex (Ed.) Nanobiomaterials in drug delivery (2016)

Blood-brain barrier (BBB) is a brain protective structure composed by endothelial cells, astrocytes and pericytes characterized by specific transport systems expressed on their surface. Moreover, the ... [more ▼]

Blood-brain barrier (BBB) is a brain protective structure composed by endothelial cells, astrocytes and pericytes characterized by specific transport systems expressed on their surface. Moreover, the tight junctions, in the paracellular space, and the adherens junctions, in the basolateral space of the endothelial cells create a physical barrier hardly crossable from the most part of common drugs. Despite the BBB is vital for the central nervous system (CNS), it restricts drug delivery to this tissue. To overcome this obstacle many drug delivery systems (DDS) have been developed. Polymeric nanocarriers, solid lipid nanocarriers (SLN) and liposomes are developed to deliver drugs otherwise not able to pass the BBB, due to their physico-chemical characteristics. Besides their capacity to pass biological barriers, the potential advantages of nanocarriers are their capability to load a high quantity of drug with low cytotoxicity. [less ▲]

Detailed reference viewed: 98 (7 ULiège)
See detailLiposomes entrapping apigenin for the treatment of glioblastoma
Karim, Reatul ULiege; Palazzo, Claudio ULiege; Dubois, Nadège ULiege et al

Poster (2015, April 17)

Detailed reference viewed: 64 (23 ULiège)
Full Text
See detailLIPOSOME CONTAINING ESTETROL FOR THE TREATMENT OF ISCHEMIA DISEASES IN PREMATURE BABIES
Palazzo, Claudio ULiege; Karim, Reatul ULiege; Mawet, Marie et al

Poster (2015, April 14)

Detailed reference viewed: 72 (16 ULiège)